Wednesday, September 23, 2026

Technology

797 articles

Nvidia's $100B OpenAI Deal Falls Through: What's Next?

Nvidia's $100B OpenAI Deal Falls Through: What's Next?

Nvidia's decision to cancel a major deal could redirect resources towards high-growth areas like gaming and AI, but it also risks a drop in stock valuation and investor confidence.

ViaNews Editorial Team
DHS Investigates Critic: Transparency Versus Civil Liberties

DHS Investigates Critic: Transparency Versus Civil Liberties

The Department of Homeland Security's recent actions have sparked a debate over increased transparency and accountability in government operations versus concerns about the erosion of civil liberties and potential chilling effects on free speech.

ViaNews Editorial Team
Target VP Sues After Global Entry Revoked Following ICE Protest

Target VP Sues After Global Entry Revoked Following ICE Protest

Increased scrutiny of government security programs like Global Entry and PreCheck may enhance privacy protections but could also erode trust between employees and employers. Target's support for employee rights presents a mixed picture.

ViaNews Editorial Team
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com